Go to the list of all blogs
Allana's Avatar
published in Blogs
Jun 16, 2026
Why Is Braskem S.A. (BAK) Stock Down -11% Today?

Why Is Braskem S.A. (BAK) Stock Down -11% Today?

Key Takeaways

  • BAK shares cratered 11.93% in after-hours trading, plunging from a previous close of $3.73 to $3.285.
  • The primary catalyst was the closing of the Novonor stake sale and the unveiling of a new controlling shareholder structure involving IG4 and Petrobras.
  • Secondary drivers include the company's severe financial distress, substantial going concern warnings, and bond defaults at its Mexican subsidiary, Braskem Idesa.
  • The move reflects deep-seated concerns about negative shareholders' equity, credit ratings languishing at CC/CCC-, and an urgent capital structure reorganization.
  • Traders are now focused on potential Chapter 11 proceedings for Braskem Idesa and any further dilution or restructuring terms that may emerge.

Braskem Faces Sharp Selloff Following Control Change

BAK, the American depositary receipt representing shares of Braskem S.A. — Brazil's largest petrochemical producer and a major global player in thermoplastic resins — suffered a brutal after-hours selloff on Monday. The stock tumbled 11.93%, falling from Friday's regular-session close of $3.73 to $3.285 in extended trading. Markets reacted swiftly to the formal closing of the long-awaited Novonor stake sale and the establishment of a new controlling shareholder framework, a development that, while resolving months of uncertainty, simultaneously cast a harsh spotlight on the company's precarious financial condition.

The Novonor Stake Sale: Resolving Uncertainty but Highlighting Risks

After months of negotiations, regulatory approvals, and market speculation, the transaction transferring control of BAK from Novonor S.A. to a consortium managed by Vórtx Capital and advised by IG4 Sol Ltda. has officially closed. The deal, which also involved PBR (Petrobras) waiving its preemptive rights earlier this year, reshapes the governance structure of Braskem at a moment of extreme financial fragility. While the resolution of the ownership overhang removes one layer of uncertainty, the after-hours price action suggests investors are far from convinced that the new controlling shareholders can swiftly stabilize the company's deteriorating balance sheet. The market's verdict was swift and unforgiving: clarity on control does not equal clarity on solvency.

Braskem's Troubling Financial Position

The selloff cannot be understood without confronting the alarming financial disclosures embedded in Braskem's recent filings. The company ended 2025 with negative shareholders' equity of R$16.5 billion, negative net working capital of R$9.8 billion, and a blunt acknowledgment from management that "substantial doubt" exists about the company's ability to continue as a going concern. Global credit rating agencies have slashed Braskem's ratings to CC (Fitch) and CCC- (S&P), levels that signal default risk is either imminent or already materializing. The company drew down a $1.0 billion standby credit facility in late 2025, a move that bought time but also underscored the depth of the liquidity crisis. For a stock already trading at deeply depressed levels, the formalization of the control change appears to have triggered a reassessment of just how severe the balance sheet damage truly is.

Braskem Idesa's Bond Defaults Add Pressure

Compounding the parent company's troubles is the dire situation at Braskem Idesa, the Mexican subsidiary that has become a financial albatross. The unit defaulted on interest payments for its 2029 bonds in November 2025, followed by a second default on its 2032 bonds in February 2026. As a result, approximately R$12.1 billion (US$2.2 billion) in debt was reclassified to current liabilities, triggering cross-default clauses and forcing the discontinuation of hedge accounting. Braskem Idesa has engaged Lazard and legal advisors to explore a capital structure reorganization, with a Chapter 11 filing under U.S. law explicitly cited as a potential path. The after-hours plunge in BAK shares reflects growing fear that the subsidiary's restructuring could impose significant losses on the parent or lead to a loss of control over a strategically important asset.

Industry-Wide Challenges in Petrochemicals

Beyond company-specific woes, Braskem operates in an industry facing a prolonged and punishing downturn. Global petrochemical spreads remain structurally compressed, crushed by weaker-than-expected demand and massive oversupply from China and the United States. In Mexico, Braskem Idesa has faced material constraints on ethane access — its primary feedstock — forcing reliance on more expensive imports. While Brazilian regulatory measures such as PRESIQ (the Special Program for the Sustainability of the Chemical Industry) and provisional antidumping duties on polyethylene imports from the U.S. and Canada offer some domestic protection, they have not been enough to offset the global margin compression that continues to erode cash generation across Braskem's operations.

Market Reaction and Technical Levels

The after-hours collapse in BAK shares occurred on significantly elevated volume relative to typical extended-session activity, signaling institutional repositioning rather than retail-driven noise. The move diverged sharply from broader Brazilian equity benchmarks and U.S. major indices, confirming that the selloff was driven by company-specific catalysts rather than macro contagion. Technically, the plunge shattered the psychologically important $3.50 level, which had served as a fragile floor during recent sessions, and pushed the stock deeper into territory not seen since the depths of the 2025 petrochemical rout. The breach of this support level may invite further technical selling pressure in the regular session ahead.

Navigating Volatility with AI Tools

In volatile market environments like the one currently engulfing BAK, I often review algorithmic signals to help contextualize rapid price moves. Tickeron's Trending AI Robots page curates a selection of hundreds of AI-powered trading bots, each designed to execute specific strategies across thousands of tickers. Only the strongest performers under current market conditions are featured in this dynamically updated section. Bots vary by strategy type, timeframe, performance metrics, and the symbols they trade, offering a diverse toolkit for traders seeking data-driven decision-making. I find exploring this page provides valuable insight into which algorithmic approaches are currently adapting best to turbulent conditions like those facing Braskem.

Outlook for BAK Shares

The road ahead for BAK is fraught with binary outcomes. The newly installed controlling shareholders face the immediate challenge of executing a comprehensive capital structure reorganization that satisfies creditors while preserving equity value — a balancing act that history shows rarely leaves existing shareholders unscathed. The Braskem Idesa restructuring negotiations with the ad-hoc bondholder group remain ongoing, and any Chapter 11 filing would introduce legal complexities and potential consolidation losses. On the regulatory front, the full implementation of PRESIQ in 2027 and the outcome of final antidumping determinations could provide marginal relief, but they are unlikely to offset the structural overhang of negative equity and looming debt maturities. Upcoming earnings reports and any disclosures around the stand-by credit facility's renewal — or failure to renew — will be critical inflection points. For now, the market is pricing in a significant probability that the restructuring process extracts a heavy toll on current shareholders.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BAK

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


BAK's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for BAK turned positive on August 21, 2026. Looking at past instances where BAK's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BAK's RSI Oscillator exited the oversold zone, of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

BAK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BAK as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 50-day moving average for BAK moved below the 200-day moving average on July 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BAK entered a downward trend on August 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BAK's P/B Ratio (142.857) is very high in comparison to the industry average of (9.778). BAK has a moderately low P/E Ratio (0.000) as compared to the industry average of (33.814). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (20.317). BAK has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.037). P/S Ratio (0.058) is also within normal values, averaging (1.454).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BAK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

Notable companies

The most notable companies in this group are Dow (NYSE:DOW).

Industry description

The major diversified chemicals industry includes companies that produce a wide range of chemicals and industrial gases. The products are often used as raw materials in the manufacturing of various types of goods, including plastics, paints, carpets, and fixtures to name a few. Major companies making diversified chemicals include DuPont de Nemours Inc., Celanese Corporation, Celanese Corporation and Westlake Chemical Corporation.

Market Cap

The average market capitalization across the Chemicals: Major Diversified Industry is 2.65B. The market cap for tickers in the group ranges from 80.4K to 89.01B. SHECF holds the highest valuation in this group at 89.01B. The lowest valued company is DEVV at 80.4K.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Major Diversified Industry was 2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -5%. LXU experienced the highest price growth at 9%, while TROX experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Major Diversified Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 38
Price Growth Rating: 60
SMR Rating: 88
Profit Risk Rating: 86
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
BAK
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of petrochemicals and other related products

Industry ChemicalsMajorDiversified

Profile
Details
Industry
Chemicals Specialty
Address
Rua Lemos Monteiro
Phone
+55 1135769000
Employees
8668
Web
https://www.braskem.com.br
Interact to see
Advertisement
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
Why Is Braskem S.A. (BAK) Stock Down -11% Today?